Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy

In the current clinical study, attempts are made to assess the safety and efficacy of omega-3 fatty acids by comparing between omega-3 fatty acids and the placebo in Korean patients with IgA nephropathy.

Inclusion criteria

• Patient of both sexes age 18 or above
• Biopsy-proven IgA nephropathy
• Baseline serum creatinine ≥ 1.2mg/dl(Female),≥ 1.4mg/dl(Male)
• Able to give written informed consent

Exclusion criteria

• Hypertension SBP>160mmHg and/or DBP>100mmHg
• Subject, who in the investigator's opinion, has a systemic disease that would contraindicate participation in this study
• Use of omega-3 fatty acids or analog supplement
• Pregnancy or breast feeding at time of entry or unwillingness to comply with measures for contraception
• Current or recent (within 30 days) exposure to any investigational drug
• Subject who has hypersensitivity to this agent as a previous illness
• Low platelet(<100,000/㎕) or the subject who has a high risk of bleeding
• Use of corticosteroid during the treatment period or less than 3 months prior to the screening
• Use of anticoagulant during the treatment period or within 1 month or 6 half lives prior to screening
• Subject who in the investigator's opinion, would be confronted with a difficulty